Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Petershill Partners aggregate partner-firm AuM grows in H1

(Sharecast News) - Investment company Petershill Partners said on Friday that aggregate partner-firm assets under management had grown in the six months ended 30 June. Petershill Partners said aggregate partner-firm AuM had increased 11% during H1 to $332.0bn, while aggregate fee-paying partner-firm AuM rose 21% year-on-year to $238.0bn.

The FTSE 250-listed firm said its organic gross fee-eligible AuM raise was $14.0bn for the half, while partner-firm realisations came in at $8.0bn. It also noted that the investment performance of partner-firm funds had led to a decrease of $1.0bn in fee-paying partner-firm AuM during Q2 but remained stable for H1 as a whole.

Petershill kept its full-year guidance unchanged and expects to deliver $20.0bn-25.0bn of organic fee-eligible AuM raise and realisations of $5.0bn-10.0bn in fee-paying AuM during FY24. Company adjusted underlying earnings margins were pegged to come in at roughly 85-90%.

As of 0920 BST, Petershill shares were up 0.71% at 211.50p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

PepsiCo cuts revenue outlook again
(Sharecast News) - PepsiCo cut its annual organic revenue guidance again on Tuesday as it highlighted a "subdued" performance in North America in the third quarter.
Berenberg lowers target price on Impax Asset Management
(Sharecast News) - Analysts at Berenberg lowered their target price on Impax Asset Management from 620.0p to 560.0p on Tuesday but noted that outflows had started to slow.
GSK's Arexvy provides protection over three RSV seasons, trial shows
(Sharecast News) - GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three seasons.
S&U revenue up, profitability a challenge in first half
(Sharecast News) - Motor and property finance specialist S&U reported a mixed first-half financial performance on Tuesday, after group revenue increased 9% year-on-year to £60.4m.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.